Safety Study of Fondaparinux Sodium to Prevent Venous Thromboembolic Events (APOLLO) [clinicaltrials:NCT00038961]

Bio2RDF identifier

NCT00038961

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00038961

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00038961

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

1.309

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00038961 arm group 072beeb9de4b80ac737d1175855bc2f2 [clinicaltrials_resource:NCT00038961/arm-group/072beeb9de4b80ac737d1175855bc2f2]

NCT00038961 arm group a14d0b5a2a4052ebd09d9f633bedbc79 [clinicaltrials_resource:NCT00038961/arm-group/a14d0b5a2a4052ebd09d9f633bedbc79]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This study is a randomi ...... tment period (day 5-9).

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety Study of Fondaparinux Sodium to Prevent Venous Thromboembolic Events (APOLLO)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:34bc6935f37c636087f99c84ca44bc08]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:b126be26abc195694588217f6b965c62]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:11586527dcd5eb882c2e71ea8153dbec]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:1b0eb925c7a67931107c34a17a2de001]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:20c2c51f55f401202303349af534cedc]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:3e119c6503e0be57968233368b12eee5]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:407574a131a3966a3392d18a15a361be]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:668988f0ec85ec4f956682c48376e8ac]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:6d8914a835be60685930ec130b9a6f33]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:9f8c1244ec789bdc4ccc9ea571418e7a]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:bcaa8caef7d196c0951cd68c7ac1227b]

venous thromboembolism (VTE adjudicated mandatory venogram positive for DVT between day 5 and day 10; up to day 10 for symptomatic DVT and/or adjudicated non fatal Pe , adjudicated fatal PE [clinicaltrials_resource:c8fc6778f25805e49936c7b2b0f28e1b]

collaborator [clinicaltrials_vocabulary:collaborator]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

completion date [clinicaltrials_vocabulary:completion-date]

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00038961 [clinicaltrials_resource:e7ed11d371159de817341fec1fdf5364]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2002-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo [clinicaltrials_resource:3bed5c6d1329d1a946be4ef15e9a8059]

Fondaparinux Sodium [clinicaltrials_resource:e8105e5082c1cfbe6f989f4abefe6855]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

PENTA [clinicaltrials_resource:335465b2e290f18eaac2c28ce3a9f52e]

Fondaparinux [clinicaltrials_resource:bade3410652d4c9d16821e88bc1bd889]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

DVT Prevention

http://www.w3.org/2001/XMLSchema#string

Major Abdominal Surgery

http://www.w3.org/2001/XMLSchema#string

VTE prevention

http://www.w3.org/2001/XMLSchema#string

Venous Thromboembolic

http://www.w3.org/2001/XMLSchema#string

abdominal surgery

http://www.w3.org/2001/XMLSchema#string

fondaparinux sodium

http://www.w3.org/2001/XMLSchema#string

pulmonary embolism

http://www.w3.org/2001/XMLSchema#string

venous thromboembolism

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

Princeton Baptist Medical Center [clinicaltrials_resource:9b712a5da3c01f1eb782619eae22a15f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00038961

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Multicenter, Randomized, Dou ...... rgoing Major Abdominal Surgery

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

103.414

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

EFC3558

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00038961 study design [clinicaltrials_resource:ef65e68c616693a4b22126fad66c40d3]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00038961

verification date [clinicaltrials_vocabulary:verification-date]

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00038961

http://www.w3.org/2001/XMLSchema#string

title

Safety Study of Fondaparinux Sodium to Prevent Venous Thromboembolic Events (APOLLO)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]